BenevolentAI Investor Conference Presentation Deck
Cash runway to Q4-2024 providing sufficient capital for
key value inflection points
Cash Runway
Cash at 30th June 2022
H2 2022 cash spend
£165m
£36m-£40m
BEN-2293 trial costs (c.£15m) fall away in 2023
Cash runway guidance assumes no future
capital from licensing or collaboration
agreements
Multiple assets at or close to key value
inflection points and ready for out-licensing
Benevolent
Capital allocation
Fund Phase I/II trial for BEN-2293 in Atopic Dermatitis
(before subsequent out-license)
Fund Phase I trial for BEN-8744 in Ulcerative Colitis and
commencement of Phase II trial in 2024
Prioritisation of clinical spend on target Therapeutic
Indications, with 2 Phase I trial starts by 2025
Continuous enhancement of the Benevolent Platform™
Investment to support listing status and further
collaborations
Benevolent 16View entire presentation